Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
RBD-7022 by Suzhou Ribo Life Sciences for Hyperlipidemia: Likelihood of Approval
RBD-7022 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hyperlipidemia. According to GlobalData,...